---
title: "信達生物宣佈 Jaypirca 已獲得中國國家藥品監督管理局的批准"
description: "信達生物表示，Jaypirca 已獲得中國國家藥品監督管理局（NMPA）的批准"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277222255.md"
published_at: "2026-02-27T15:31:11.000Z"
---

# 信達生物宣佈 Jaypirca 已獲得中國國家藥品監督管理局的批准

> 信達生物表示，Jaypirca 已獲得中國國家藥品監督管理局（NMPA）的批准

### Related Stocks

- [589720.CN - 國泰上證科創板創新藥ETF](https://longbridge.com/zh-HK/quote/589720.CN.md)
- [512290.CN - 國泰中證生物醫藥ETF](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [159615.CN - 南方恆生生物科技ETF(QDII)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [513120.CN - 廣發中證香港創新藥(QDII-ETF)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [159859.CN - 天弘國證生物醫藥ETF](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [560600.CN - 方正富邦中證醫藥及醫療器械創新ETF](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [516820.CN - 平安中證醫療創新ETF](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [588860.CN - 科創醫藥ETF工銀](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [159506.CN - 富國恆生港股通創新藥及醫療保健ETF](https://longbridge.com/zh-HK/quote/159506.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hangzhou Jiuyuan’s Semaglutide Biosimilar Jikeqin Advances Toward China Market Approval | Hangzhou Jiuyuan Gene Engineering Co Ltd has developed Jikeqin, a biosimilar of semaglutide for weight management. The d | [Link](https://longbridge.com/zh-HK/news/276936312.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-HK/news/276549711.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/zh-HK/news/276822785.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-HK/news/276886600.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-HK/news/276718382.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。